Rosiglitazone: A review of its use in type 2 diabetes mellitus

Drugs

Volumn 67, Issue 18, 2007, Pages 2747-2779

  Deeks, Emma D ^a   Keam, Susan J ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Adis Drug Evaluations; Rosiglitazone, general; Type 2 diabetes mellitus, treatment

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ALBUMIN; ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; ATORVASTATIN; BIGUANIDE DERIVATIVE; DIGOXIN; DIURETIC AGENT; ETHINYLESTRADIOL; FENOFIBRATE; GLIBENCLAMIDE; GLIMEPIRIDE; GLIPIZIDE; GLYCOSYLATED HEMOGLOBIN; INSULIN; INSULIN DERIVATIVE; INSULIN GLARGINE; MEGLITINIDE; METFORMIN; NIFEDIPINE; NORETHISTERONE; PIOGLITAZONE; RANITIDINE; REPAGLINIDE; ROSIGLITAZONE; SULFONYLUREA; UNINDEXED DRUG; VILDAGLIPTIN; WARFARIN;

ANEMIA; BACKACHE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DATA BASE; DIARRHEA; DISEASE COURSE; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFECT; DRUG ELIMINATION; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; EMBASE; FATIGUE; FRACTURE; GLUCOSE BLOOD LEVEL; HEADACHE; HEALTH PERCEPTIONS QUESTIONNAIRE; HEART FAILURE; HEMATOCRIT; HUMAN; HYPERGLYCEMIA; HYPERLACTATEMIA; HYPOGLYCEMIA; INJURY; INSULIN SENSITIVITY; LIVER FAILURE; MEDLINE; METHODOLOGY; MICROALBUMINURIA; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBSERVATIONAL STUDY; PANCREAS ISLET BETA CELL; PATIENT SATISFACTION; REVIEW; RISK FACTOR; SIDE EFFECT; SINUSITIS; STATISTICAL ANALYSIS; UPPER RESPIRATORY TRACT INFECTION; WEIGHT GAIN;

EID: 36849081979     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200767180-00008     Document Type: Review

References (142)

1. World Health Organization. Diabetes [online]. Available from URL: http://www.who.int/mediacentre/factsheets/fs312/en/print/html [Accessed 2007 May 11]
2. Wild S, Roglic G, Green A, et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004 May; 27 (5): 1047-53
3. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2005 Jan; 28 Suppl. 1: S37-42
4. International Diabetes Federation. Diabetes e-atlas [online]. Available from URL: http://www.eatlas.idf.org [Accessed 2007 Jul 25]
5. Wagstaff AJ, Goa KL. Rosiglitazone: a review of its use in the management of type 2 diabetes mellitus [published erratum appears in Drugs 2003; 63 (11): 1163]. Drugs 2002; 62 (12): 1805-37
6. Bhatt DL, Chew DP, Grines C, et al. Peroxisome proliferator-activated receptor γ agonists for the prevention of adverse events following percutaneous coronary revascularization: results of the PPAR study [published erratum appears in Am Heart J 2007; 154 (2): 402]. Am Heart J 2007 Jul; 154 (1): 137-43
7. Rosenstock J, Baron MA, Dejager S, et al. Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabetes Care 2007 Feb; 30 (2): 217-23
8. Yki-J̈arvinen H. Thiazolidinediones. N Eng J Med 2004 Sep 9; 351 (11): 1106-18
9. Armoni M, Kritz N, Harel C, et al. Peroxisome proliferator-activated receptor-γ represses GLUT4 promoter activity in primary adipocytes, and rosiglitazone alleviates this effect. J Biol Chem 2003 Aug 15; 278 (33): 30614-23
10. Hernandez R, Teruel T, Lorenzo M. Rosiglitazone produces insulin sensitisation by increasing expression of the insulin receptor and its tyrosine kinase activity in brown adipocytes. Diabetologia 2003 Dec; 46 (12): 1618-28
11. Sun X, Han R, Wang Z, et al. Regulation of adiponectin receptors in hepatocytes by the peroxisome proliferator-activated receptor-γ agonist rosiglitazone. Diabetologia 2006 Jun; 49 (6): 1303-10
12. Tan GD, Debard C, Funahashi T, et al. Changes in adiponectin receptor expression in muscle and adipose tissue of type 2 diabetic patients during rosiglitazone therapy. Diabetologia 2005 Aug; 48 (8): 1585-9
13. Leiter LA. Can thiazolidinediones delay disease progression in type 2 diabetes? Curr Med Res Opin 2006 Jun; 22 (6): 1193-201
14. Hanefeld M, Patwardhan R, Jones NP. A one-year study comparing the efficacy and safety of rosiglitazone and glibenclamide in the treatment of type 2 diabetes. Nutr Metab Cardiovasc Dis 2007 Jan; 17 (1): 13-23
15. Gastaldelli A, Ferrannini E, Miyazaki Y, et al. Thiazolidinedi-ones improve beta-cell function in type 2 diabetic patients. Am J Physiol Endocrinol Metab 2007 Mar; 292 (3): E871-83
16. Lebovitz HE, Dole JF, Patwardhan R, et al. Rosiglitazone monotherapy is effective in patients with type 2 diabetes [published erratum appears in J Clin Endocrinol Metab 2001; 86: 1659]. J Clin Endocrinol Metab 2001; 86 (1): 280-8
17. Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy [published erratum appears in N Engl J Med 2007; 356 (13): 1387-8]. N Engl J Med 2006 Dec 7; 355 (23): 2427-43
18. Smith SA, Porter LE, Biswas N, et al. Rosiglitazone, but not glyburide, reduces circulating proinsulin and the proinsulin:insulin ratio in type 2 diabetes. J Clin Endocrinol Metab 2004 Dec; 89 (12): 6048-53
19. Rosenstock J, Goldstein BJ, Vinik AI, et al. Effect of early addition of rosiglitazone to sulphonylurea therapy in older type 2 diabetes patients (>60 years): the Rosiglitazone Early vs. SULphonylurea Titration (RESULT) study. Diabetes Obes Metab 2006 Jan; 8 (1): 49-57
20. Krauss RM. Lipids and lipoproteins in patients with type 2 diabetes. Diabetes Care 2004 Jun; 27 (6): 1496-504
21. Phillips LS, Grunberger G, Miller E, et al. Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes [published erratum appears in Diabetes Care 2001; 24 (5): 973]. Diabetes Care 2001; 24 (2): 308-15
22. Nolan JJ, Jones NP, Patwardhan R, et al. Rosiglitazone taken once daily provides effective glycaemic control in patients with type 2 diabetes mellitus. Diabet Med 2000; 17 (4): 287-94
23. Raskin P, Rappaport EB, Cole ST, et al. Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with type II diabetes. Diabetologia 2000; 43 (3): 278-84
24. Lebovitz HE, Kreider M, Freed MI. Evaluation of liver function in type 2 diabetic patients during clinical trials. Diabetes Care 2002 May; 25 (5): 815-21
25. Goldberg RB, Kendall DM, Deeg MA, et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2005 Jul; 28 (7): 1547-54
26. Bailey CJ, Bagdonas A, Rubes J, et al. Rosiglitazone/metformin fixed-dose combination compared with uptitrated metformin alone in type 2 diabetes mellitus: a 24-week, multicenter, randomized, double-blind, parallel-group study. Clin Ther 2005; 27 (10): 1548-61
27. Fonseca V, Rosenstock J, Patwardhan R, et al. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. JAMA 2000; 283: 1695-702
28. Home PD, Jones NP, Pocock SJ, et al. Rosiglitazone RECORD study: glucose control outcomes at 18 months. Diabet Med 2007 Jun; 24 (6): 626-34
29. Kerenyi Z, Samer H, James R, et al. Combination therapy with rosiglitazone and glibenclamide compared with upward titration of glibenclamide alone in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract 2004 Mar; 63 (3): 213-23
30. Rosenstock J, Sugimoto D, Strange P, et al. Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insu- Peroxlin-naive patients. Diabetes Care 2006 Mar; 29 (3): 554-9
31. Baksi A, James RE, Zhou B, et al. Comparison of uptitration of gliclazide with the addition of rosiglitazone to gliclazide in patients with type 2 diabetes inadequately controlled on half-maximal doses of a sulphonylurea. Acta Diabetol 2004 Jun; 41 (2): 63-9
32. Yang J, Di F, He R, et al. Effect of addition of low-dose rosiglitazone to sulphonylurea therapy on glycemic control in type 2 diabetic patients. Chin Med J (Engl) 2003 May; 116 (5): 785-7
33. Deeg MA, Buse JB, Goldberg RB, et al. Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2007 Oct; 30 (10): 2458-64
34. Freed MI, Ratner R, Marcovina SM, et al. Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes mellitus. Am J Cardiol 2002 Nov 1; 90 (9): 947-52
35. Chu CS, Lee KT, Lee MY, et al. Effects of rosiglitazone alone and in combination with atorvastatin on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Am J Cardiol 2006 Mar 1; 97 (5): 646-50
36. Yue T-L, Chen J, Bao W, et al. In vivo myocardial protection from ischemia/reperfusion injury by the peroxisome proliferator-activated receptor-γ agonist rosiglitazone. Circulation 2001; 104: 2588-94
37. Sidell RJ, Cole MA, Draper NJ, et al. Thiazolidinedione treatment normalizes insulin resistance and ischemic injury in the Zucker fatty rat heart. Diabetes 2002 Apr; 51: 1110-7
38. 2-terminal kinase/activating protein 1 pathway and protects the heart from ischemia/reperfusion injury. Diabetes 2002 May; 51 (5): 1507-14
39. St John Sutton M, Rendell M, Dandona P, et al. A comparison of the effects of rosiglitazone and glyburide on cardiovascular culfunction and glycemic control in patients with type 2 diabetes. Diabetes Care 2002 Nov; 25 (11): 2058-64
40. Patel J, Anderson RJ, Rappaport EB. Rosiglitazone monotherapy improves glycemic control in patients with type 2 diabetes: a twelve-week, randomized, placebo-controlled study. Diabetes Obes Metab 1999; 1: 165-72
41. Hallsten K, Virtanen KA, Lonnqvist F, et al. Enhancement of insulin-stimulated myocardial glucose uptake in patients with type 2 diabetes treated with rosiglitazone. Diabet Med 2004 Dec; 21 (12): 1280-7
42. Gao DF, Niu XL, Hao GH, et al. Rosiglitazone inhibits angiotensin II-induced CTGF expression in vascular smooth muscle cells: role of PPAR-gamma in vascular fibrosis. Biochem Pharmacol 2007 Jan 15; 73 (2): 185-97
43. Law RE, Goetze S, Xi X-P, et al. Expression and function of PPARγ in rat and human vascular smooth muscle cells. Circulation 2000 Mar 21; 101 (11): 1311-8
44. Rahman S, Ismail AA, Ismail SB, et al. Effect of rosiglitazone/ramipril on preclinical vasculopathy in newly diagnosed, untreated diabetes and IGT patients: 1-year randomised, double-blind, placebo-controlled study. Eur J Clin Pharmacol 2007 Aug; 63 (8): 733-41
45. Walker AB, Chattington PD, Buckingham RE, et al. The thiazolidinedione rosiglitazone (BRL-49653) lowers blood pressure and protects against impairment of endothelial function in Zucker fatty rats. Diabetes 1999; 48: 1448-53
46. Buckingham RE, Al-Barazanji KA, Toseland CDN, et al. Peroxisome proliferator-activated receptor-γ agonist, rosiglitazone, protects against nephropathy and pancreatic islet abnormalities in Zucker fatty rats. Diabetes 1998; 47: 1326-34
47. Natali A, Baldeweg S, Toschi E, et al. Vascular effects of improving metabolic control with metformin or rosiglitazone in type 2 diabetes. Diabetes Care 2004 Jun; 27 (6): 1349-57
48. Nilsson PM, Hedblad B, Donaldson J, et al. Rosiglitazone reduces office and diastolic ambulatory blood pressure follow-type ing 1-year treatment in non-diabetic subjects with insulin resistance. Blood Press 2007; 16 (2): 95-100
49. Stühlinger MC, Abbasi F, Chu JW, et al. Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. JAMA 2002 Mar 20; 287 (11): 1420-6
50. Osei K, Gaillard T, Kaplow J, et al. Effects of rosiglitazone on plasma adiponectin, insulin sensitivity, and insulin secretion in high-risk African Americans with impaired glucose tolerance test and type 2 diabetes. Metabolism 2004 Dec; 53 (12): 1552-7
51. van Doorn M, Kemme M, Ouwens M, et al. Evaluation of proinflammatory cytokines and inflammation markers as biomarkers for the action of thiazolidinediones in type 2 diabetes mellitus patients and healthy volunteers. Br J Clin Pharmacol 2006 Oct; 62 (4): 391-402
52. Albertini JP, McMorn SO, Chen H, et al. Effect of rosiglitazone on factors related to endothelial dysfunction in patients with type 2 diabetes mellitus. Atherosclerosis 2007 Nov; 195 (1): e159-66
53. Haffner SM, Greenberg AS, Weston WM, et al. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 2002 Aug 6; 106 (6): 679-84
54. Maeda N, Takahashi M, Funahashi T, et al. PPAR-γ ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 2001 Sep; 50: 2094-9
55. Pistrosch F, Herbrig K, Oelschlaegel U, et al. PPARγ-agonist rosiglitazone increases number and migratory activity of cultured endothelial progenitor cells. Atherosclerosis 2005; 183 (1): 163-7
56. Cuzzocrea S, Pisano B, Dugo L, et al. Rosiglitazone, a ligand of the peroxisome proliferator-activated receptor-γ, reduces acute inflammation. Eur J Pharmacol 2004 Jan 1; 483 (1): 79-93
57. Kolak M, Yki-Jarvinen H, Kannisto K, et al. Effects of chronic rosiglitazone therapy on gene expression in human adipose tissue in vivo in patients with type 2 diabetes. J Clin Endocrinol Metab 2007 Feb; 92 (2): 720-4
58. Bakris G, Viberti G, Weston WM, et al. Rosiglitazone reduces urinary albumin excretion in type II diabetes. J Hum Hypertens 2003 Jan; 17 (1): 7-12
59. Pistrosch F, Passauer J, Fischer S, et al. In type 2 diabetes, rosiglitazone therapy for insulin resistance ameliorates endothelial dysfunction independent of glucose control. Diabetes Care 2004 Feb; 27 (2): 484-90
60. Tan GD, Fielding BA, Currie JM, et al. The effects of rosiglitazone on fatty acid and triglyceride metabolism in type 2 diabetes. Diabetologia 2005 Jan; 48 (1): 83-95
61. Petrofsky J, Lee S, Bweir S, et al. Improvement in dermal neural vascular function with rosiglitazone in individuals with type II diabetes. J Applied Res 2004; 4 (3): 499-507
62. Sotiropoulos KB, Clermont A, Yasuda Y, et al. Adipose-specific effect of rosiglitazone on vascular permeability and protein kinase C activation: novel mechanism for PPARγ agonist's effects on edema and weight gain. FASEB J 2006 Jun; 20 (8): 1203-5
63. Nesto RW, Bell D, Bonow RO, et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care 2004 Jan; 27 (1): 256-63
64. Soroceanu MA, Miao D, Bai XY, et al. Rosiglitazone impacts negatively on bone by promoting osteoblast/osteocyte apoptosis. J Endocrinol 2004 Oct; 183 (1): 203-16
65. European Medicines Agency. Avandia: summary of product characteristics [online]. Available from URL: http://www.emea.europa.eu/humandocs/PDFs/EPAR/ Avandia/H-268-PI-en.pdf [Accessed 2007 Oct 1]
66. Nilsson P, Hedblad B, Zambanini A, et al. Rosiglitazone reduces carotid intima-media thickness progression over 1 year in patients with type 2 diabetes but not in non-diabetic people who have insulin resistance alone [abstract no. A40]. Diabet Med 2006 Mar; 23 Suppl. 2: 11
67. Tostes GCU, Silva MER, Fukui RT, et al. Efficacy of nateglinide or rosiglitazone therapy on glycemic control and serum inflammatory markers in type 2 diabetes patients [abstract no. P1-620]. 88th Annual Meeting of the Endocrine Society; 2006 Jun 24-27; Boston (MA), 319
68. Miyazaki Y, Cersosimo E, DeFronzo RA. Rosiglitazone decreases urinary albumin excretion in association with alteration of circulating adipocytokine levels in type 2 diabetes patients [abstract no. 455-P]. Diabetes 2005 Jun; 54 Suppl. 1: 112
69. Vrablik M, Dobiasova M, Stulc T, et al. Rosiglitazone improves quality of lipoproteins in patients with type 2 diabetes [abstract no. We-P11:117]. Atherosclerosis 2006 Jun 1; 7 Suppl. 3: 371
70. Lautamaki R, Ronnemaa T, Airaksinen KEJ, et al. Rosiglitazone increases the concentration of large, buoyant but not small dense LDL in patients with type 2 diabetes and coronary artery disease, a 16 week randomised, double-blind, placebo-controlled study [abstract no. 498-P]. Diabetes 2005 Jun; 54 Suppl. 1: 123
71. Shinall S, Buse J, Tan M, et al. Glycaemic and lipid effects of pioglitazone and rosiglitazone in patients naive to oral antidiabetic medications [abstract no. 1160]. Diabetologia 2006; 49 Suppl. 1: 703-4. Plus a poster presented at the 42nd meeting of the European Association for the Study of Diabetes; 2006 Sep 14-17; Copenhagen
72. Osei K, Gaillard T, Cook C, et al. Thiazolidinediones (TZD) increase plasma adiponectin (ADIP) levels but not tissue ADIPO and ADIPO receptor R1 and R2 gene expression in African-Americans (AA) [abstract no. P729]. Diabet Med 2006 Dec 1; 23 Suppl. 4: 270
73. Seber S, Ucak S, Basat O, et al. The effect of dual PPAR alpha/gamma stimulation with combination of rosiglitazone and fenofibrate on metabolic parameters in type 2 diabetic patients. Diabetes Res Clin Pract 2006 Jan; 71 (1): 52-8
74. Normén L, Frolich J, Montaner J, et al. Combination therapy with fenofibrate and rosiglitazone paradoxically lowers serum HDL cholesterol. Diabetes Care 2004 Sep; 27 (9): 2241-2
75. Zhang H, Zhang A, Kohan DE, et al. Collecting duct-specific deletion of peroxisome proliferator-activated receptor γ blocks thiazolidinedione- induced fluid retention. Proc Natl Acad Sci U S A 2005 Jun 28; 102 (26): 9406-11
76. Grey A, Bolland M, Gamble G, et al. The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial. J Clin Endocrinol Metab 2007 Apr; 92 (4): 1305-10
77. Ali AA, Weinstein RS, Stewart SA, et al. Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation. Endocrinology 2005 Mar; 146 (3): 1226-35
78. Pasco JA, Henry MJ, Nicholson GC. Weight gain may contribute to increased fracture risk in women treated with rosigltazone. Diabet Med 2007 Oct; 24 (10): 1173-4
79. GlaxoSmithKline. AVANDIA (rosiglitazone maleate) tablets: prescribing information [online]. Available from URL: http://www.fda.gov/cder/foi/label/ 2007/021071s031lbl.pdf [Accessed 2007 Nov 20]
80. Patel BR, Diringer K, Conrad J, et al. Population pharmacokinetics of rosiglitazone in phase III clinical trials [abstract no. PII-33]. Clin Pharmacol Ther 2000; 67 (2): 123
81. DiCicco R, Freed M, Allen A, et al. A study of the effect of age on the pharmacokinetics of BRL 49653C in healthy volunteers [abstract no. 24]. J Clin Pharmacol 1995 Sep; 35: 926
82. Miller AK, Inglis AL, Thompson K, et al. Effect of hepatic impairment on the pharmacokinetics (PK) of rosiglitazone (RSG) [abstract no. PIII-37]. Clin Pharmacol Ther 1999 Feb; 65 (2): 186
83. Cox PJ, Ryan DA, Hollis FJ, et al. Absorption, disposition, and metabolism of rosiglitazone, a potent thiazolidinedione insulin sensitizer, in humans. Drug Metab Dispos 2000 Jul; 28 (7): 772-80
84. Baldwin SJ, Clarke SE, Chenery RJ. Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of rosiglitazone. Br J Clin Pharmacol 1999 Sep; 48 (3): 424-32
85. Chaplesky MC, Thompson-Culkin K, Miller AK, et al. Pharmacokinetics of rosiglitazone in patients with varying degrees of renal insufficiency. J Clin Pharmacol 2003 Mar; 43 (3): 252-9
86. Thompson-Culkin K, Zussman B, Miller AK, et al. Pharmacokinetics of rosiglitazone in patients with end-stage renal disdisease, ease. J Int Med Res 2002 Jul-Aug; 30 (4): 391-9
87. Home PD, Bailey CJ, Donaldson J, et al. A double-blind randomized study comparing the effects of continuing or not continuing rosiglitazone + metformin therapy when starting insulin therapy in people with type 2 diabetes. Diabet Med 2007 Apr 2; 24 (6): 618-25
88. Rosenstock J, Ferreira-Cornwell C, Weston WM, et al. Rosiglitazone added early to glimepiride provides superior glycemic control than uptitration of glimepiride alone in type 2 diabetes (T2DM) [abstract no. 549-P]. Diabetes 2005; 54 Suppl. 1: A136. Plus poster presented at the 65th Scientific Sessions of the American Diabetes Association; 2005 Jun 10-14; San Diego (CA)
89. Bakris GL, Ruilope LM, McMorn SO, et al. Rosiglitazone reduces microalbuminuria and blood pressure independently of glycemia in type 2 diabetes patients with microalbuminuria. J Hypertens 2006 Oct; 24 (10): 2047-55
90. Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD): study design and protocol. Diabetologia 2005 Sep; 48 (9): 1726-35
91. Rosak C, Standl E, Reblin T, et al. Rosiglitazone is effective and well-tolerated in a range of therapeutic regimens during daily practice in patients with type 2 diabetes. Int J Clin Pract 2006 Sep; 60 (9): 1040-7
92. Electronic Medicines Compendium. Avandia 4mg and 8mg tablets: summary of product characteristics [online]. Available from URL: http://www.emc.medicines. org.uk/emc/assets/c/html/displayDocPrinterFriendly.asp?documentid=3200 [Accessed 2007 Jul 2]
93. Viberti G, Kahn SE, Greene DA, et al. A Diabetes Outcome Progression Trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care 2002 Oct; 25 (10): 1737-43
94. Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes: an interim analysis. N Engl J Med 2007 Jul 5; 357 (1): 28-38
95. European Medicines Agency. Galvus®: prescribing information [online]. Available from URL: http://www.emea.europa.eu/humandocs/PDFs/EPAR/galvus/H-771- PI-en.pdf [Accessed 2007 Oct 5]
96. European Medicines Agency. European Medicines Agency confirms positive benefit-risk balance for rosiglitazone and piog- Pharmalitazone [online]. Available from URL: http://www.emea.europa.eu/pdfs/human/press/pr/48427707en.pdf [Accessed 2007 22 Nov]
97. European Medicines Agency. Committee for Medicinal Products for Human Use: post-authorisation summary of positive opinion for Avandia [online]. Available from URL: http://www.emea.europa.eu/pdfs/human/opinion/ avandia_30697207en.pdf [Accessed 2007 Oct 30]
98. European Medicines Agency. Avandamet: summary of product characteristics [online]. Available from URL: http://www.emea.europa.eu/humandocs/PDFs/EPAR/ avandamet/H-522-PI-en.pdf [Accessed 2007 Jul 2]
99. Vinik AI, Zhang Q. Adding insulin glargine versus rosiglitazone: health-related quality-of-life impact in type 2 diabetes. Diabetes Care 2007; 30 (4): 795-800
100. Tilden DP, Mariz S, O'Bryan-Tear G, et al. A lifetime modelled economic evaluation comparing pioglitazone and rosiglitazone for the treatment of type 2 diabetes mellitus in the UK [published erratum appears in Pharmacoeconomics 2007; 25 (3): 237]. Pharmacoeconomics 2007; 25 (1): 39-54
101. Beale S, Bagust A, Shearer AT, et al. Cost-effectiveness of rosiglitazone combination therapy for the treatment of type 2 diabetes mellitus in the UK. Pharmacoeconomics 2006; 24 Suppl. 1: 21-34
102. Shearer AT, Bagust A, Liebl A, et al. Cost-effectiveness of rosiglitazone oral combination for the treatment of type 2 diabetes in Germany. Pharmacoeconomics 2006; 24 Suppl. 1: 35-48
103. Home P, Bagust A, Taylor M, et al. A lifetime modelled economic evaluation comparing pioglitazone and rosiglitazone for the treatment of type 2 diabetes mellitus in the UK. Pharmacoeconomics 2007; 25 (9): 801-2
104. Tilden DP, Mariz S, O'Bryan-Tear G, et al. The author's reply [letter]. Pharmacoeconomics 2007; 25 (9): 802-5
105. Charbonnel B, Schernthaner G, Brunetti P, et al. Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes. Diabetologia 2005 Jun; 48 (6): 1093-104
106. Wright A, Burden ACF, Paisey RB, et al. Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the UK Prospective Study (UKPDS 57). Diabetes Care 2002 Feb; 25 (2): 330-6
107. Liebl A, Neiss A, Spannheimer A, et al. Complications, comorbidity and blood glucose control in type 2 diabetes mellitus patients in Germany: results from the CODE-2 study. Exp Clin Endocrinol Diabetes 2002 Jan; 110 (1): 10-6
108. Liebl A, Neiss A, Spannheimer A, et al. Costs of type 2 diabetes in Germany: results of the CODE-2 study. Dtsch Med Wochenschr 2001 May 18; 126 (20): 585-9
109. Karalliedde J, Buckingham R, Starkie M, et al. Effect of various diuretic treatments on rosiglitazone-induced fluid retention. J Am Soc Nephrol 2006 Dec; 17 (12): 3482-90
110. Boden G, Homko C, Mozzoli M, et al. Combined use of rosiglitazone and fenofibrate in patients with type 2 diabetes: prevention of fluid retention. Diabetes 2007 Jan; 56 (1): 248-55
111. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes [published erratum appears in N Engl J Med 2007 Jul 5; 357 (1): 100]. N Engl J Med 2007 Jun 14; 356 (24): 2457-71
112. McAfee AT, Koro C, Landon J, et al. Coronary heart disease outcomes in patients receiving antidiabetic agents. Pharmalitazone coepidemiol Drug Saf 2007 Jul; 16 (7): 711-25
113. Singh S, Loke YK, Furberg CD. Long-term risk of cardiocessed vascular events with rosiglitazone: a meta-analysis. JAMA 2007 Sep 12; 298 (10): 1189-95
114. GlaxoSmithKline Ltd. AVANDIA® cardiovascular event modeling project (study no. ZM2005/00181/01) and coronary heart disease outcomes in patients receiving antidiabetic agents (study no. HM2006/00497/00/WEUSRTP866) [online]. Available from URL: http://ctr.gsk.co.uk/Summary/rosiglitazone/studylist.asp [Accessed 2007 May 5]
115. Rosen CJ. The rosiglitazone story: lessons from an FDA advisory committee meeting. N Engl J Med 2007 Aug 30; 357 (9): 844-6
116. GlaxoSmithKline. Advisory committee briefing document: cardiovascular safety of rosiglitazone [online]. Available from URL: http://www.fda.gov/ohrms/ dockets/ac/07/briefing/2007-4308b1-01-sponsor-backgrounder.pdf [Accessed 2007 Oct 1]
117. GlaxoSmithKline Ltd. AVANDAMET® (rosiglitazone maleate and metformin hydrochloride): US prescribing information [online]. Available from URL: http://www.fda.gov/cder/foi/label/2007/021410s019lbl.pdf [Accessed 2007 Jul 23]
118. National Institute for Clinical Excellence. Guidance on the use of glitazones for the treatment of type 2 diabetes [online]. Available from URL: http://www.nice.org.uk/nicemedia/pdf/TA63_Glitazones_Review_Guidance.pdf [Accessed 2007 Jul 17]
119. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998 Sep 12; 352 (9131): 837-53
120. The Action to Control Cardiovascular Risk in Diabetes (ACCORD) Study Group. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. Am J Cardiol 2007 Jun 18; 99 (12 Suppl. 1): 21-33i
121. International Diabetes Federation. Global guideline for type 2 diabetes [online]. Available from URL: http://www.idf.org/webdata/docs/IDF%20GGT2D.pdf [Accessed 2007 Jul 17]
122. National Institute for Clinical Excellence. Clinical guidelines for type 2 diabetes: management of blood glucose [online]. Available from URL: http://guidance.nice.org.uk/download.aspx?o=36881 [Accessed 2007 Jul 17]
123. American Diabetes Association. Standards of medical care in diabetes: 2007. Diabetes Care 2007 Jan; 30 Suppl. 1: S4-41
124. American Association of Clinical Endocrinologists. Medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Prac 2007 May-Jun 30; 13 Suppl. 1: 1-68
125. Ahrén B. Dipeptidyl peptidase-4 inhibitors: clinical data and preclinical implications. Diabetes Care 2007 Jun; 30 (6): 1344-50
126. Levetan C. Oral antidiabetic agents in type 2 diabetes. Curr Med Res Opin 2007 Apr; 23 (4): 945-52
127. Todd JF, Bloom SR. Incretins and other peptides in the treatment of diabetes. Diabet Med 2007 Mar; 24 (3): 223-32
128. Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2006 Aug; 29 (8): 1963-72
129. Lago RM, Singh PP, Nesto RW. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-anaylsis of randomised clinical trials. Lancet 2007 Sep 29; 370: 1129-36
130. Irons BK, Greene RS, Mazzolini TA, et al. Implications of rosiglitazone and pioglitazone on cardiovascular risk in patients with type 2 diabetes mellitus. Pharmacotherapy 2006 Feb; 26 (2): 168-81
131. Diamond GA, Bax L, Kaul S. Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death [letter]. Ann Intern Med 2007 Oct 16; 147 (8): 578-81
132. Shuster JJ, Jones LS, Salmon DA. Fixed vs random effects meta-analysis in rare event studies: the rosiglitazone link with myocardial infarction and cardiac death. Stat Med 2007 Oct 30; 26 (24): 4375-85
133. McCullough PA, Lepor NE. The rosiglitazone meta-analysis [published erratum appears in Rev Cardiovasc Med 2007; 8 (3): 174]. Rev Cardiovasc Med 2007; 8 (2): 123-6
134. Magee MF, Isley WL. Rationale, design, and methods for glycemic control in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial. Am J Cardiol 2006 Jun 19; 97 (12A): 20-30G
135. European Medicines Agency. Post-authorisation evaluation of medicines for human use: questions and answers on the benefits and risks of rosiglitazone and pioglitazone [online]. Available from URL: http://www.emea.europa.eu/pdfs/ human/preclinicalss/pr/48446407en.pdf [Accessed 2007 Nov 1]
136. Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005 Oct 8; 366 (9493): 1279-89
137. Lincoff AM, Wolski K, Nicholls SJ, et al. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 2007 Sep 12; 298 (10): 1180-8
138. Gerrits CM, Bhattacharya M, Manthena S, et al. A comparison of pioglitazone and rosiglitazone for hospitalization for acute myocardial infarction in type 2 diabetes. Pharmacoepidemiol Drug Saf 2007 Oct; 16 (10): 1065-71
139. Psaty BM, Furberg CD. Rosiglitazone and cardiovascular risk. N Engl J Med 2007 Jun 14; 356 (24): 2522-4
140. Nathan DM. Rosiglitazone and cardiotoxicity: weighing the evidence [letter]. N Engl J Med 2007 Jul 5; 357 (1): 64-6
141. Takeda Pharmaceutical Company Ltd. ACTOS® (pioglitazone hydrochloride): prescribing information [online]. Available from URL: http://www.fda.gov/cder/foi/label/2007/021073s030lbl.pdf [Accessed 2007 Oct 1]
142. Takeda Pharmaceutical Company Ltd. Re: Observation of an increased incidence of fractures in female patients who received long-term treatment with ACTOS® (pioglitazone HCl) tablets for type 2 diabetes mellitus [online]. Available from URL: http://www.fda.gov/medwatch/safety/2007/safety07.htm#Actos [Accessed 2007 Jul 20]